Drug intelligence / Profile preview

PH-PARP06

Development stage: Preclinical
Modality: Small Molecules

Overview

PH-PARP06 is a novel small molecule PARP inhibitor discovered through chemical space expansion efforts, demonstrating potent inhibition of poly(ADP-ribose) polymerase (PARP) activity. It induces G2/M cell cycle arrest and apoptosis in cancer cells, positioning it as a potential anti-cancer agent for tumors reliant on DNA repair pathways.[1]

Targets

PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on PH-PARP06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PH-PARP06.

Explore the full profile